[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Buprenorphine.]
[M03AB01, succinylcholine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[J01EC02, sulfadiazine, The metabolism of Buprenorphine can be decreased when combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Buprenorphine can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The metabolism of Buprenorphine can be decreased when combined with Sulfamethoxazole.]
[J01EC03, sulfamoxole, The metabolism of Buprenorphine can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The metabolism of Buprenorphine can be decreased when combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Buprenorphine can be decreased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The metabolism of Buprenorphine can be decreased when combined with Sulfisoxazole.]
[N05AL01, sulpiride, Sulpiride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N03AX03, sulthiame, Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Buprenorphine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Buprenorphine.]
[N05CD07, temazepam, Temazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Buprenorphine.]
[G03BA03, testosterone, Buprenorphine may decrease the excretion rate of Testosterone which could result in a higher serum level.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be decreased when combined with Buprenorphine.]
[S01HA03, tetracaine, Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AE05, lurasidone, Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N04BC07, apomorphine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L04AX02, thalidomide, Buprenorphine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, The therapeutic efficacy of Theobromine can be decreased when used in combination with Buprenorphine.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Buprenorphine.]
[R06AD03, thiethylperazine, Thiethylperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Buprenorphine.]
[N05CA19, thiopental, Thiopental may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AB08, thioproperazine, Thioproperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AC02, thioridazine, Thioridazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AF04, thiothixene, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Buprenorphine.]
[N05AL03, tiapride, Tiapride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[B01AC05, ticlopidine, The metabolism of Ticlopidine can be decreased when combined with Buprenorphine.]
[N02AX01, tilidine, Tilidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Buprenorphine.]
[A10BB05, tolazamide, The metabolism of Buprenorphine can be decreased when combined with Tolazamide.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Buprenorphine.]
[M03BX04, tolperisone, Tolperisone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Buprenorphine is combined with Tramadol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AX05, trazodone, Trazodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01XF01, tretinoin, The metabolism of Buprenorphine can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The metabolism of Buprenorphine can be increased when combined with Triamcinolone.]
[C03DB02, triamterene, The therapeutic efficacy of Triamterene can be decreased when used in combination with Buprenorphine.]
[N05CD05, triazolam, Triazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Buprenorphine.]
[A03AB12, mepenzolate, The risk or severity of adverse effects can be increased when Mepenzolate is combined with Buprenorphine.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AD02, trifluperidol, Trifluperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AA05, triflupromazine, Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N04AA01, trihexyphenidyl, The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Buprenorphine.]
[R03BA07, mometasone, The metabolism of Buprenorphine can be increased when combined with Mometasone.]
[A03AA05, trimebutine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Buprenorphine.]
[R06AD01, trimeprazine, Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N03AC02, trimethadione, Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Trimethaphan is combined with Buprenorphine.]
[J01EA01, trimethoprim, The metabolism of Buprenorphine can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, Trimipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R06AC04, tripelennamine, The metabolism of Buprenorphine can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A03BB01, butylscopolamine, The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Buprenorphine.]
[J01FA08, troleandomycin, The metabolism of Buprenorphine can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AX02, tryptophan, Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M03AA02, tubocurarine, Tubocurarine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Buprenorphine.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Buprenorphine.]
[L02BX03, abiraterone, The metabolism of Buprenorphine can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Buprenorphine can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The serum concentration of Buprenorphine can be increased when it is combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Buprenorphine can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Buprenorphine can be decreased when combined with Rilpivirine.]
[N03AX21, ezogabine, Ezogabine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[B01AF01, rivaroxaban, Buprenorphine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[B01AC24, ticagrelor, Buprenorphine can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08DA01, verapamil, The metabolism of Buprenorphine can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, Viloxazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be decreased when combined with Buprenorphine.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Buprenorphine.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Buprenorphine.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Buprenorphine.]
[C03BA10, xipamide, The therapeutic efficacy of Xipamide can be decreased when used in combination with Buprenorphine.]
[J05AF01, zidovudine, The metabolism of Buprenorphine can be increased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[J05AE02, indinavir, The metabolism of Buprenorphine can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be decreased when combined with Buprenorphine.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Buprenorphine.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Buprenorphine.]
[R03DC01, zafirlukast, The metabolism of Buprenorphine can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The metabolism of Rabeprazole can be decreased when combined with Buprenorphine.]
[N05AE04, ziprasidone, Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[G03AC10, drospirenone, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Buprenorphine.]
[N02BA01, aspirin, The metabolism of Acetylsalicylic acid can be decreased when combined with Buprenorphine.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Buprenorphine.]
[G04BD07, tolterodine, The risk or severity of adverse effects can be increased when Tolterodine is combined with Buprenorphine.]
[C07AB03, atenolol, The metabolism of Atenolol can be decreased when combined with Buprenorphine.]
[J02AC03, voriconazole, The metabolism of Buprenorphine can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, Atracurium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S01FA01, atropine, The risk or severity of adverse effects can be increased when Atropine is combined with Buprenorphine.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Buprenorphine.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Buprenorphine.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Buprenorphine.]
[H02AB11, prednylidene, The metabolism of Buprenorphine can be increased when combined with Prednylidene.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Buprenorphine.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A08AA11, lorcaserin, Lorcaserin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[G04BD12, mirabegron, The serum concentration of Buprenorphine can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The serum concentration of Buprenorphine can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Buprenorphine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Buprenorphine can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Buprenorphine.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Buprenorphine.]
[L04AA31, teriflunomide, The metabolism of Buprenorphine can be decreased when combined with Teriflunomide.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Buprenorphine.]
[N05CA04, barbital, Barbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[J05AE04, nelfinavir, The metabolism of Buprenorphine can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N04BD02, rasagiline, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C08CA13, lercanidipine, The metabolism of Buprenorphine can be decreased when combined with Lercanidipine.]
[A03FA09, mosapride, Mosapride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06DA02, donepezil, Donepezil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Buprenorphine.]
[N02CC03, zolmitriptan, Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R06AC06, thonzylamine, The risk or severity of adverse effects can be increased when Thonzylamine is combined with Buprenorphine.]
[G04BD10, darifenacin, The risk or severity of adverse effects can be increased when Darifenacin is combined with Buprenorphine.]
[N01AA01, ethyl ether, Diethyl ether may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01EX07, cabozantinib, The metabolism of Buprenorphine can be decreased when combined with Cabozantinib.]
[G04BE03, sildenafil, The metabolism of Buprenorphine can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Buprenorphine.]
[B01AF02, apixaban, Buprenorphine may decrease the excretion rate of Apixaban which could result in a higher serum level.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Buprenorphine.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Buprenorphine.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Buprenorphine can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Buprenorphine.]
[L04AX06, pomalidomide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[G03XC05, ospemifene, The metabolism of Buprenorphine can be decreased when combined with Ospemifene.]
[N05AD07, benperidol, Benperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Buprenorphine.]
[M04AB03, benzbromarone, The metabolism of Buprenorphine can be decreased when combined with Benzbromarone.]
[A06AX06, tegaserod, The metabolism of Buprenorphine can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M01AH01, celecoxib, The metabolism of Buprenorphine can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Buprenorphine.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Benzatropine is combined with Buprenorphine.]
[L01EC02, dabrafenib, The serum concentration of Buprenorphine can be decreased when it is combined with Dabrafenib.]
[L01EE01, trametinib, The metabolism of Buprenorphine can be decreased when combined with Trametinib.]
[P03AX06, benzyl alcohol, Benzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01EB03, afatinib, Buprenorphine may decrease the excretion rate of Afatinib which could result in a higher serum level.]
[N06AX28, levomilnacipran, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[J05AJ03, dolutegravir, Buprenorphine may decrease the excretion rate of Dolutegravir which could result in a higher serum level.]
[C08EA02, bepridil, The metabolism of Buprenorphine can be decreased when combined with Bepridil.]
[C02KX05, riociguat, Buprenorphine may decrease the excretion rate of Riociguat which could result in a higher serum level.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Buprenorphine.]
[N06AX26, vortioxetine, Vortioxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N03AF04, eslicarbazepine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[J05AP05, simeprevir, The metabolism of Buprenorphine can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Buprenorphine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Buprenorphine.]
[C07AB04, acebutolol, The metabolism of Buprenorphine can be decreased when combined with Acebutolol.]
[N05CH03, tasimelteon, Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A16AA07, metreleptin, The metabolism of Buprenorphine can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Buprenorphine can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The metabolism of Buprenorphine can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, The metabolism of Betaxolol can be decreased when combined with Buprenorphine.]
[C10AB02, bezafibrate, The metabolism of Buprenorphine can be decreased when combined with Bezafibrate.]
[L04AC11, siltuximab, The metabolism of Buprenorphine can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Buprenorphine.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Buprenorphine.]
[A03BA03, hyoscyamine, The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Buprenorphine.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Buprenorphine.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Buprenorphine.]
[N01AX05, alfaxalone, Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Buprenorphine.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Buprenorphine.]
[N05CM19, suvorexant, Suvorexant may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Buprenorphine.]
[J01XA05, oritavancin, The metabolism of Buprenorphine can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Buprenorphine.]
[A06AH03, naloxegol, Buprenorphine may increase the opioid antagonism activities of Naloxegol.]
[N04AA02, biperiden, The risk or severity of adverse effects can be increased when Biperiden is combined with Buprenorphine.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Buprenorphine.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Buprenorphine.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Buprenorphine.]
[J05AP09, dasabuvir, The metabolism of Buprenorphine can be decreased when combined with Dasabuvir.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Buprenorphine.]
[B01AA01, dicumarol, The metabolism of Buprenorphine can be decreased when combined with Dicoumarol.]
[N06AX11, mirtazapine, Buprenorphine may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Buprenorphine can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Buprenorphine.]
[L01EX08, lenvatinib, Buprenorphine may decrease the excretion rate of Lenvatinib which could result in a higher serum level.]
[L01XH03, panobinostat, The metabolism of Buprenorphine can be decreased when combined with Panobinostat.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be decreased when combined with Buprenorphine.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Buprenorphine.]
[A03AA09, difemerine, The risk or severity of adverse effects can be increased when Difemerine is combined with Buprenorphine.]
[J05AP06, asunaprevir, The metabolism of Buprenorphine can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Buprenorphine is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Buprenorphine.]
[A04AD14, rolapitant, The metabolism of Buprenorphine can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Buprenorphine.]
[N05AX15, cariprazine, Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S01EC01, acetazolamide, Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AB07, acetophenazine, Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Buprenorphine.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Buprenorphine.]
[J02AC05, isavuconazole, The metabolism of Buprenorphine can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Buprenorphine.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Buprenorphine.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Buprenorphine.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Buprenorphine.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Buprenorphine.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Buprenorphine.]
[A10BB31, acetohexamide, The metabolism of Buprenorphine can be decreased when combined with Acetohexamide.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Buprenorphine.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Buprenorphine.]
[J05AP10, elbasvir, The metabolism of Elbasvir can be decreased when combined with Buprenorphine.]
[N05CA05, aprobarbital, Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N03AX23, brivaracetam, Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Buprenorphine.]
[N05BA08, bromazepam, Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N04BC01, bromocriptine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A03AX08, alverine, Alverine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R06AB01, brompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AA19, amineptin, Amineptine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Buprenorphine.]
[N06BX11, aniracetam, Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C03CA02, bumetanide, The therapeutic efficacy of Bumetanide can be decreased when used in combination with Buprenorphine.]
[N01BB01, bupivacaine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C07AA19, bupranolol, The metabolism of Bupranolol can be decreased when combined with Buprenorphine.]
[S01AA13, fusidic acid, The metabolism of Buprenorphine can be decreased when combined with Fusidic acid.]
[N05BE01, buspirone, Buspirone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Buprenorphine.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Buprenorphine.]
[M02AA03, clofezone, The metabolism of Rabeprazole can be decreased when combined with Buprenorphine.]
[N02AF01, butorphanol, Butorphanol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S01GX07, azelastine, Buprenorphine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Buprenorphine can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Azithromycin can be decreased when combined with Buprenorphine.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Buprenorphine.]
[L01EF02, ribociclib, The metabolism of Buprenorphine can be decreased when combined with Ribociclib.]
[A06AH05, naldemedine, The therapeutic efficacy of Buprenorphine can be decreased when used in combination with Naldemedine.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be decreased when combined with Buprenorphine.]
[N02BF02, pregabalin, Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N03AX30, beclamide, Beclamide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S01HA02, benoxinate, Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome and opioid toxicity can be increased when Buprenorphine is combined with Linezolid.]
[J05AE09, tipranavir, The metabolism of Buprenorphine can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Buprenorphine.]
[L04AB02, infliximab, The metabolism of Buprenorphine can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Buprenorphine can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Buprenorphine.]
[N04BD03, safinamide, Safinamide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[J01MA23, delafloxacin, Buprenorphine may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[L01BC06, capecitabine, The metabolism of Buprenorphine can be decreased when combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Buprenorphine.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Buprenorphine.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Buprenorphine.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Buprenorphine.]
[J05AG03, efavirenz, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be decreased when combined with Buprenorphine.]
[N04AA11, bornaprine, The risk or severity of adverse effects can be increased when Bornaprine is combined with Buprenorphine.]
[N05AD06, bromperidol, Bromperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CD09, brotizolam, Brotizolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C03DA03, canrenone, The therapeutic efficacy of Canrenone can be decreased when used in combination with Buprenorphine.]
[R03BA02, budesonide, The metabolism of Buprenorphine can be increased when combined with Budesonide.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Buprenorphine.]
[N05CA03, butobarbital, Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[J05AX18, letermovir, The metabolism of Buprenorphine can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, Butriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A10BK04, ertugliflozin, Buprenorphine may decrease the excretion rate of Ertugliflozin which could result in a higher serum level.]
[N05CA08, butylvinal, Vinylbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02BB05, apalutamide, The metabolism of Buprenorphine can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, Carbamazepine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Buprenorphine.]
[A03AA03, camylofine, The risk or severity of adverse effects can be increased when Camylofin is combined with Buprenorphine.]
[R06AA08, carbinoxamine, Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Buprenorphine.]
[B02BX09, fostamatinib, The metabolism of Buprenorphine can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, Cannabidiol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[B02BX08, avatrombopag, The metabolism of Buprenorphine can be increased when combined with Avatrombopag.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Buprenorphine.]
[C07AB08, celiprolol, The metabolism of Celiprolol can be decreased when combined with Buprenorphine.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Buprenorphine.]
[L01XX62, ivosidenib, The metabolism of Buprenorphine can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Buprenorphine.]
[N03AX17, stiripentol, Stiripentol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[B02BX07, lusutrombopag, Buprenorphine may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.]
[J05AX24, tecovirimat, The metabolism of Buprenorphine can be increased when combined with Tecovirimat.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Buprenorphine.]
[L01EM04, duvelisib, Buprenorphine may decrease the excretion rate of Duvelisib which could result in a higher serum level.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Buprenorphine.]
[S01GX12, cetirizine, Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CM04, carbromal, Carbromal may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Buprenorphine.]
[N01BA04, chloroprocaine, Chloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R06AA06, chlorphenoxamine, The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Buprenorphine.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be decreased when combined with Buprenorphine.]
[L01XK04, talazoparib, Buprenorphine may decrease the excretion rate of Talazoparib which could result in a higher serum level.]
[M03BA02, carisoprodol, Carisoprodol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R03BB08, revefenacin, The risk or severity of adverse effects can be increased when Revefenacin is combined with Buprenorphine.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be decreased when combined with Buprenorphine.]
[L04AA39, emapalumab, The metabolism of Buprenorphine can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be decreased when combined with Buprenorphine.]
[L01XJ03, glasdegib, Buprenorphine may decrease the excretion rate of Glasdegib which could result in a higher serum level.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Buprenorphine.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be increased when it is combined with Buprenorphine.]
[A03FA08, cinitapride, Cinitapride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[P02BX04, triclabendazole, The metabolism of Buprenorphine can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, Esketamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Buprenorphine.]
[J01FA09, clarithromycin, The metabolism of Buprenorphine can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, Solriamfetol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AX29, brexanolone, Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Buprenorphine.]
[N05BA09, clobazam, Clobazam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[H02AB14, cloprednol, The metabolism of Buprenorphine can be increased when combined with Cloprednol.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Buprenorphine.]
[N05BA22, cloxazolam, Cloxazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C09CA06, candesartan, The metabolism of Buprenorphine can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Buprenorphine can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Buprenorphine can be increased when combined with Cortivazol.]
[L01EM03, alpelisib, The serum concentration of Alpelisib can be increased when it is combined with Buprenorphine.]
[L02BB06, darolutamide, Buprenorphine may decrease the excretion rate of Darolutamide which could result in a higher serum level.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Buprenorphine.]
[N05AA06, cyamemazine, Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C03BX03, cicletanine, The therapeutic efficacy of Cicletanine can be decreased when used in combination with Buprenorphine.]
[M03BX08, cyclobenzaprine, Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Buprenorphine.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be decreased when combined with Buprenorphine.]
[N07XX11, pitolisant, The serum concentration of Buprenorphine can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be decreased when combined with Buprenorphine.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be decreased when combined with Buprenorphine.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Buprenorphine.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Buprenorphine.]
[G04BE04, yohimbine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Buprenorphine.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Buprenorphine.]
[N02CC08, lasmiditan, Lasmiditan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Buprenorphine.]
[G03AC09, desogestrel, The metabolism of Buprenorphine can be increased when combined with Desogestrel.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Buprenorphine.]
[N03AX25, cenobamate, The serum concentration of Buprenorphine can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Buprenorphine can be increased when it is combined with Givosiran.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Buprenorphine.]
[R06AB06, dexbrompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R06AB02, dexchlorpheniramine, The metabolism of Buprenorphine can be decreased when combined with Dexchlorpheniramine.]
[N02AX03, dezocine, Dezocine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01EX18, avapritinib, The metabolism of Buprenorphine can be decreased when combined with Avapritinib.]
[N05CM21, lemborexant, Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01XX72, tazemetostat, Buprenorphine may decrease the excretion rate of Tazemetostat which could result in a higher serum level.]
[N05AD10, lumateperone, Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M01AX21, diacetylrhein, The metabolism of Buprenorphine can be decreased when combined with Diacerein.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Buprenorphine.]
[H02CA02, osilodrostat, The metabolism of Buprenorphine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Buprenorphine can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, Frovatriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be decreased when combined with Buprenorphine.]
[L04AA38, ozanimod, Buprenorphine may decrease the excretion rate of Ozanimod which could result in a higher serum level.]
[N05CC04, dichloralphenazone, Dichloralphenazone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01EE04, selumetinib, Buprenorphine may decrease the excretion rate of Selumetinib which could result in a higher serum level.]
[A07DA04, difenoxin, Difenoxin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02AA08, dihydrocodeine, Dihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02CC06, eletriptan, Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M01AH02, rofecoxib, The metabolism of Buprenorphine can be decreased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Buprenorphine can be decreased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Buprenorphine can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, The metabolism of Buprenorphine can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, Valpromide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S03AA08, chloramphenicol, The metabolism of Buprenorphine can be decreased when combined with Chloramphenicol.]
[N05BA02, chlordiazepoxide, Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Buprenorphine.]
[A03AA08, dihexyverine, The risk or severity of adverse effects can be increased when Dihexyverine is combined with Buprenorphine.]
[D07XB03, fluprednidene, The metabolism of Buprenorphine can be increased when combined with Fluprednidene.]
[G04BD09, trospium, The risk or severity of adverse effects can be increased when Trospium is combined with Buprenorphine.]
[L01EX19, ripretinib, Buprenorphine may decrease the excretion rate of Ripretinib which could result in a higher serum level.]
[L01EX22, selpercatinib, The serum concentration of Buprenorphine can be increased when it is combined with Selpercatinib.]
[N05CM02, chlormethiazole, Clomethiazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M03BB02, chlormezanone, Chlormezanone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R02AD04, dyclonine, Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Buprenorphine.]
[R06AX22, ebastine, The metabolism of Ebastine can be decreased when combined with Buprenorphine.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Buprenorphine.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Buprenorphine is combined with Remimazolam.]
[N07XX04, sodium oxybate, Buprenorphine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[L04AC19, satralizumab, The serum concentration of Buprenorphine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Buprenorphine is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Buprenorphine can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, Buprenorphine may decrease the excretion rate of Pralsetinib which could result in a higher serum level.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Buprenorphine.]
[R06AB04, chlorpheniramine, Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AA01, chlorpromazine, Chlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A10BB02, chlorpropamide, The metabolism of Buprenorphine can be decreased when combined with Chlorpropamide.]
[N05AF03, chlorprothixene, Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Buprenorphine.]
[M03BB03, chlorzoxazone, Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A11CC05, cholecalciferol, The metabolism of Buprenorphine can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, Etifoxine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06BX18, vinpocetine, Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BA18, ethyl loflazepate, Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M01AB08, etodolac, The metabolism of Buprenorphine can be decreased when combined with Etodolac.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Buprenorphine.]
[A16AX20, lonafarnib, The metabolism of Buprenorphine can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The metabolism of Relugolix can be decreased when combined with Buprenorphine.]
[P03AX07, abametapir, The serum concentration of Buprenorphine can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The metabolism of Buprenorphine can be decreased when combined with Tepotinib.]
[V03AF12, trilaciclib, Buprenorphine may decrease the excretion rate of Trilaciclib which could result in a higher serum level.]
[M03BA05, febarbamate, Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N03AX10, felbamate, Felbamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[G04CB01, finasteride, The metabolism of Finasteride can be decreased when combined with Buprenorphine.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Buprenorphine.]
[L04AA50, ponesimod, The metabolism of Ponesimod can be decreased when combined with Buprenorphine.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L03AB10, peginterferon alfa-2b, The metabolism of Buprenorphine can be decreased when combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The metabolism of Buprenorphine can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Buprenorphine.]
[L01XX73, sotorasib, The serum concentration of Buprenorphine can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Buprenorphine.]
[S03AA07, ciprofloxacin, The metabolism of Buprenorphine can be decreased when combined with Ciprofloxacin.]
[N06AB04, citalopram, Citalopram may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Buprenorphine.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Buprenorphine.]
[L01XX74, belzutifan, The serum concentration of Belzutifan can be increased when it is combined with Buprenorphine.]
[L01EB10, mobocertinib, The metabolism of Mobocertinib can be decreased when combined with Buprenorphine.]
[R06AA04, clemastine, Clemastine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M01AG01, mefenamic acid, The metabolism of Buprenorphine can be decreased when combined with Mefenamic acid.]
[A10BB12, glimepiride, The metabolism of Buprenorphine can be decreased when combined with Glimepiride.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Buprenorphine.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be decreased when combined with Buprenorphine.]
[N06AX25, St. John's wort extract, St. John's Wort may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01EA06, asciminib, The metabolism of Buprenorphine can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Buprenorphine.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Buprenorphine.]
[J04BA01, clofazimine, The metabolism of Buprenorphine can be decreased when combined with Clofazimine.]
[B06AX04, mitapivat, The metabolism of Buprenorphine can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AA04, clomipramine, Clomipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N03AE01, clonazepam, Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Buprenorphine.]
[C01EB24, mavacamten, The serum concentration of Buprenorphine can be decreased when it is combined with Mavacamten.]
[C03BA03, clopamide, The therapeutic efficacy of Clopamide can be decreased when used in combination with Buprenorphine.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Buprenorphine.]
[N05AH06, clothiapine, Clothiapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[H01CC04, linzagolix, The serum concentration of Buprenorphine can be increased when it is combined with Linzagolix.]
[N05BA21, clotiazepam, Clotiazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A04AA01, ondansetron, Ondansetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A04AA02, granisetron, Granisetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AH02, clozapine, Clozapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BA13, halazepam, Halazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[H01AC08, somatrogon, The metabolism of Buprenorphine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of adverse effects can be increased when Cocaine is combined with Buprenorphine.]
[C02KB01, metyrosine, Buprenorphine may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Buprenorphine can be increased when combined with Bimekizumab.]
[R05DA04, codeine, Codeine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M03AC05, hexafluorenium, Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Buprenorphine.]
[A03AB10, hexocyclium, The risk or severity of adverse effects can be increased when Hexocyclium is combined with Buprenorphine.]
[A03BB06, homatropine methylbromide, The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Buprenorphine.]
[L04AA13, leflunomide, Buprenorphine may decrease the excretion rate of Leflunomide which could result in a higher serum level.]
[N01AB07, desflurane, Desflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A04AA03, tropisetron, Tropisetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C04AX28, ifenprodil, Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A10BX03, nateglinide, The metabolism of Buprenorphine can be decreased when combined with Nateglinide.]
[J01FA15, telithromycin, The metabolism of Buprenorphine can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Buprenorphine.]
[R06AX27, desloratadine, Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M01AH03, valdecoxib, The metabolism of Buprenorphine can be decreased when combined with Valdecoxib.]
[H01AX01, pegvisomant, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Buprenorphine.]
[N02CC05, almotriptan, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Buprenorphine.]
[J02AC02, itraconazole, The metabolism of Buprenorphine can be decreased when combined with Itraconazole.]
[N05BA10, ketazolam, Ketazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01EA01, imatinib, The serum concentration of Buprenorphine can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Buprenorphine can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Esomeprazole can be decreased when combined with Buprenorphine.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Buprenorphine.]
[N03AX09, lamotrigine, Lamotrigine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S01GX02, levocabastine, Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S01BA03, cortisone, The metabolism of Buprenorphine can be increased when combined with Cortisone.]
[N07BC04, lofexidine, Lofexidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R06AX13, loratadine, The metabolism of Buprenorphine can be decreased when combined with Loratadine.]
[N05CD06, lormetazepam, Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Buprenorphine.]
[C08CA11, manidipine, The metabolism of Buprenorphine can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, The risk or severity of adverse effects can be increased when Mebeverine is combined with Buprenorphine.]
[N06AX13, medifoxamine, Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Buprenorphine.]
[H02AB15, meprednisone, The metabolism of Buprenorphine can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Mequitazine can be decreased when combined with Buprenorphine.]
[N04AA03, methixene, The risk or severity of adverse effects can be increased when Metixene is combined with Buprenorphine.]
[R03CB02, methoxyphenamine, Methoxyphenamine may increase the analgesic activities of Buprenorphine.]
[R06AE03, cyclizine, Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CA10, cyclobarbital, Cyclobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C03DA04, eplerenone, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Buprenorphine.]
[N05AD03, metylperon, Melperone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Buprenorphine.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Buprenorphine.]
[N06AX07, minaprine, Minaprine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S01XA18, cyclosporine, The metabolism of Buprenorphine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06BA07, modafinil, The metabolism of Buprenorphine can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C10AA07, rosuvastatin, Buprenorphine may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.]
[C03XA02, conivaptan, The metabolism of Buprenorphine can be decreased when combined with Conivaptan.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Buprenorphine.]
[M01AH05, etoricoxib, The metabolism of Buprenorphine can be decreased when combined with Etoricoxib.]
[L01DA01, dactinomycin, Buprenorphine may decrease the excretion rate of Dactinomycin which could result in a higher serum level.]
[G03XA01, danazol, The metabolism of Buprenorphine can be decreased when combined with Danazol.]
[M03CA01, dantrolene, Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[J04BA02, dapsone, The metabolism of Buprenorphine can be decreased when combined with Dapsone.]
[L01DB02, daunorubicin, Buprenorphine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[N06BX04, deanol, Deanol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Buprenorphine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M01AX01, nabumetone, The metabolism of Buprenorphine can be decreased when combined with Nabumetone.]
[N07BB05, nalmefene, The therapeutic efficacy of Buprenorphine can be decreased when used in combination with Nalmefene.]
[B05XA15, potassium lactate, The therapeutic efficacy of Potassium lactate can be decreased when used in combination with Buprenorphine.]
[N05BA16, nordazepam, Nordazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Buprenorphine.]
[N06AX06, nefazodone, Nefazodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CM16, niaprazine, Niaprazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02BB02, nilutamide, The metabolism of Buprenorphine can be decreased when combined with Nilutamide.]
[N03AG06, tiagabine, Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M03AC11, cisatracurium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R05DA06, normethadone, Normethadone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AB10, escitalopram, Escitalopram may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[G04BD08, solifenacin, The risk or severity of adverse effects can be increased when Solifenacin is combined with Buprenorphine.]
[N06AA01, desipramine, Desipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[H01BA02, desmopressin, The risk or severity of hyponatremia can be increased when Buprenorphine is combined with Desmopressin.]
[L01XA03, oxaliplatin, Buprenorphine may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.]
[N03AF02, oxcarbazepine, Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S03BA01, dexamethasone, The metabolism of Buprenorphine can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N04AA08, dexetimide, The risk or severity of adverse effects can be increased when Dexetimide is combined with Buprenorphine.]
[G04BD04, oxybutynin, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Buprenorphine.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Buprenorphine is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Buprenorphine.]
[L04AB04, adalimumab, The metabolism of Buprenorphine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, Buprenorphine may decrease the excretion rate of Gefitinib which could result in a higher serum level.]
[N06BA02, dextroamphetamine, Amphetamine may increase the analgesic activities of Buprenorphine.]
[R05DA09, dextromethorphan, Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N03AC01, paramethadione, Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02AC01, dextromoramide, Dextromoramide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AB05, paroxetine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[B01AC04, clopidogrel, Buprenorphine can cause a decrease in the absorption of Clopidogrel resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N07BC06, heroin, Diamorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BA01, diazepam, Diazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N03AX07, phenacemide, Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N03AD02, phensuximide, Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AA08, dibenzepin, Dibenzepin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S02DA04, dibucaine, Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S01EC02, dichlorphenamide, The therapeutic efficacy of Diclofenamide can be decreased when used in combination with Buprenorphine.]
[S01BC03, diclofenac, The metabolism of Buprenorphine can be decreased when combined with Diclofenac.]
[A03AA07, dicyclomine, The risk or severity of adverse effects can be increased when Dicyclomine is combined with Buprenorphine.]
[A10BG03, pioglitazone, The metabolism of Buprenorphine can be decreased when combined with Pioglitazone.]
[N05AD05, pipamperone, Pipamperone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A03AB14, pipenzolate, The risk or severity of adverse effects can be increased when Pipenzolate is combined with Buprenorphine.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Buprenorphine.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Buprenorphine.]
[C03CA03, piretanide, The therapeutic efficacy of Piretanide can be decreased when used in combination with Buprenorphine.]
[A08AA03, diethylpropion, Diethylpropion may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AA01, diethylstilbestrol, The metabolism of Buprenorphine can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Buprenorphine can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Buprenorphine can be increased when combined with Difluocortolone.]
[A03AB11, poldine, The risk or severity of adverse effects can be increased when Poldine is combined with Buprenorphine.]
[N02BA11, diflunisal, The metabolism of Buprenorphine can be decreased when combined with Diflunisal.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Buprenorphine.]
[C10AX09, ezetimibe, Buprenorphine may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be decreased when combined with Buprenorphine.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02AA03, hydromorphone, Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[J05AE08, atazanavir, The metabolism of Buprenorphine can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Buprenorphine can be decreased when combined with Treprostinil.]
[D04AB07, pramoxine, Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C08DB01, diltiazem, The metabolism of Buprenorphine can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M03BX03, pridinol, Pridinol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R06AB03, dimethindene, The risk or severity of adverse effects can be increased when Dimetindene is combined with Buprenorphine.]
[M02AX03, dimethyl sulfoxide, The metabolism of Buprenorphine can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, Progabide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C05CA03, diosmin, The metabolism of Buprenorphine can be decreased when combined with Diosmin.]
[R06AA02, diphenhydramine, Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A07DA01, diphenoxylate, Diphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CD10, quazepam, Quazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AA23, quinupramine, Quinupramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A03FA02, cisapride, Cisapride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Buprenorphine.]
[N05AL04, remoxipride, Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C01BA03, disopyramide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Buprenorphine.]
[P03AA04, disulfiram, The metabolism of Buprenorphine can be decreased when combined with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Buprenorphine can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Buprenorphine can be increased when combined with Rifapentine.]
[N07XX02, riluzole, Riluzole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AX08, risperidone, Risperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R06AE09, levocetirizine, Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N01BB09, ropivacaine, Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Buprenorphine.]
[A04AD12, aprepitant, The metabolism of Buprenorphine can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Buprenorphine.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Buprenorphine.]
[G04BE08, tadalafil, The metabolism of Buprenorphine can be decreased when combined with Tadalafil.]
[S01BC05, ketorolac, The metabolism of Buprenorphine can be decreased when combined with Ketorolac.]
[C02KX02, ambrisentan, The metabolism of Ambrisentan can be decreased when combined with Buprenorphine.]
[C01EB18, ranolazine, The serum concentration of Buprenorphine can be increased when it is combined with Ranolazine.]
[R03AC12, salmeterol, The metabolism of Buprenorphine can be decreased when combined with Salmeterol.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Buprenorphine.]
[N06AA16, dothiepin, Dosulepin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AA12, doxepin, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Buprenorphine.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Buprenorphine.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AB06, sertraline, Sertraline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N01AB08, sevoflurane, Sevoflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A08AA10, sibutramine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C10AA01, simvastatin, The metabolism of Buprenorphine can be decreased when combined with Simvastatin.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Buprenorphine.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Buprenorphine.]
[N05AL02, sultopride, Sultopride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02CC01, sumatriptan, Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C07AB13, talinolol, The metabolism of Talinolol can be decreased when combined with Buprenorphine.]
[M01AC02, tenoxicam, The metabolism of Buprenorphine can be decreased when combined with Tenoxicam.]
[D01BA02, terbinafine, The metabolism of Buprenorphine can be decreased when combined with Terbinafine.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Buprenorphine.]
[M03BX07, tetrazepam, Tetrazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M03BX05, thiocolchicoside, Thiocolchicoside may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AB05, thiopropazate, Thiopropazate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[G04BD01, emepronium, Emepronium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AX14, tianeptine, Tianeptine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BA23, tofisopam, Tofisopam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AG03, toloxatone, Toloxatone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Buprenorphine.]
[N03AX11, topiramate, Topiramate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C03CA04, torsemide, The metabolism of Buprenorphine can be decreased when combined with Torasemide.]
[N05CD11, triazulenone, Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CC01, chloral hydrate, Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CM07, triclofos, Triclofos may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A03AB08, tridihexethyl, The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Buprenorphine.]
[R06AA10, trimethobenzamide, Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N04AA12, tropatepine, The risk or severity of adverse effects can be increased when Tropatepine is combined with Buprenorphine.]
[N01AB04, enflurane, Enflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C02CA06, urapidil, Urapidil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AL06, veralipride, Veralipride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Buprenorphine.]
[S01GX10, epinastine, Epinastine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AX16, venlafaxine, Venlafaxine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C08CA12, mepirodipine, The metabolism of Buprenorphine can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Buprenorphine can be decreased when combined with Epinephrine.]
[N05CF02, zolpidem, Zolpidem may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N03AX15, zonisamide, Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CF01, zopiclone, Zopiclone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AX11, zotepine, Zotepine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C02AC02, guanfacine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C01BG01, moricizine, Moricizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[G02AB03, ergonovine, Ergometrine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02CA02, ergotamine, Ergotamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S01AA17, erythromycin, The metabolism of Buprenorphine can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, Estazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A02BC02, pantoprazole, The metabolism of Pantoprazole can be decreased when combined with Buprenorphine.]
[H05BX01, cinacalcet, The metabolism of Buprenorphine can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Buprenorphine.]
[G03CA57, estrogens, conjugated (USP), Buprenorphine may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.]
[J04AK02, ethambutol, The metabolism of Buprenorphine can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The metabolism of Buprenorphine can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Buprenorphine can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Buprenorphine can be decreased when combined with Fluvastatin.]
[C01CA15, gepefrine, Gepefrine may increase the analgesic activities of Buprenorphine.]
[N05CM08, ethchlorvynol, Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AA03, ethinyl estradiol, The metabolism of Buprenorphine can be increased when combined with Ethinylestradiol.]
[N04AA05, profenamine, The risk or severity of adverse effects can be increased when Profenamine is combined with Buprenorphine.]
[N03AD01, ethosuximide, Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N03AB01, ethotoin, Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M01AC06, meloxicam, The metabolism of Buprenorphine can be decreased when combined with Meloxicam.]
[S01XA06, ethylmorphine, Ethylmorphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N01AX07, etomidate, Etomidate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Buprenorphine.]
[N05AE03, sertindole, Sertindole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Buprenorphine.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Buprenorphine.]
[R06AX12, terfenadine, The metabolism of Buprenorphine can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, Bupropion may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AB08, fluvoxamine, Fluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C01BC08, encainide, The metabolism of Encainide can be decreased when combined with Buprenorphine.]
[C10AA03, pravastatin, Buprenorphine may decrease the excretion rate of Pravastatin which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, The metabolism of Buprenorphine can be decreased when combined with Sodium aurothiomalate.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Buprenorphine.]
[C08CA02, felodipine, The metabolism of Buprenorphine can be decreased when combined with Felodipine.]
[N03AX26, fenfluramine, Fenfluramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Fenoterol is combined with Buprenorphine.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Buprenorphine.]
[L01BB06, clofarabine, Buprenorphine may decrease the excretion rate of Clofarabine which could result in a higher serum level.]
[L04AA40, cladribine, Buprenorphine may decrease the excretion rate of Cladribine which could result in a higher serum level.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Buprenorphine.]
[G04BD02, flavoxate, The risk or severity of adverse effects can be increased when Flavoxate is combined with Buprenorphine.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Buprenorphine.]
[J02AC01, fluconazole, The metabolism of Buprenorphine can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CD03, flunitrazepam, Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[D07AC08, fluocinonide, The metabolism of Buprenorphine can be increased when combined with Fluocinonide.]
[N06AA14, melitracen, Melitracen may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[H02AB03, fluocortolone, The metabolism of Buprenorphine can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, Ethanol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01BC09, floxuridine, The metabolism of Buprenorphine can be decreased when combined with Floxuridine.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Buprenorphine.]
[N06AB03, fluoxetine, Fluoxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AF01, flupenthixol, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AB02, fluphenazine, Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CD01, flurazepam, Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S01BC04, flurbiprofen, The metabolism of Buprenorphine can be decreased when combined with Flurbiprofen.]
[N05AG01, fluspirilene, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02BB01, flutamide, The metabolism of Buprenorphine can be decreased when combined with Flutamide.]
[V04CX02, folic acid, Buprenorphine may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Buprenorphine.]
[M03AA01, alcuronium, Alcuronium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[G01AX06, furazolidone, Furazolidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[J05AE10, darunavir, The serum concentration of Buprenorphine can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, The therapeutic efficacy of Furosemide can be decreased when used in combination with Buprenorphine.]
[N05CF04, eszopiclone, Eszopiclone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AL05, amisulpride, Amisulpride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Buprenorphine.]
[M03AC02, gallamine, Gallamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N03AA04, barbexaclone, Barbexaclone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AX08, bifemelane, Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C10AB04, gemfibrozil, The metabolism of Buprenorphine can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Buprenorphine.]
[N04BC06, cabergoline, Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Buprenorphine.]
[N03AD03, methsuximide, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N01AH02, alfentanil, Alfentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Buprenorphine.]
[A06AH02, alvimopan, The risk or severity of adverse effects can be increased when Buprenorphine is combined with Alvimopan.]
[A10BB01, glyburide, Buprenorphine may decrease the excretion rate of Glyburide which could result in a higher serum level.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Buprenorphine.]
[A10BB07, glipizide, The metabolism of Glipizide can be decreased when combined with Buprenorphine.]
[N05CM18, dexmedetomidine, Dexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CE01, glutethimide, Glutethimide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Buprenorphine.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Buprenorphine.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Buprenorphine.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Buprenorphine.]
[C07AB09, esmolol, The metabolism of Esmolol can be decreased when combined with Buprenorphine.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Buprenorphine.]
[P01BX01, halofantrine, The metabolism of Buprenorphine can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N01AB01, halothane, Halothane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AH04, quetiapine, Quetiapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02CX03, iprazochrome, Iprazochrome may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Buprenorphine.]
[N05CA21, allobarbital, Allobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M04AA01, allopurinol, Buprenorphine may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[C09CA01, losartan, The metabolism of Buprenorphine can be decreased when combined with Losartan.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Buprenorphine.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Buprenorphine.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Buprenorphine.]
[N05CA16, hexobarbital, Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[J05AG01, nevirapine, The metabolism of Buprenorphine can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Buprenorphine can be decreased when combined with Nilvadipine.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Buprenorphine.]
[R05DA03, hydrocodone, The therapeutic efficacy of Hydrocodone can be decreased when used in combination with Buprenorphine.]
[S02BA01, hydrocortisone, The metabolism of Buprenorphine can be increased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Buprenorphine.]
[A12BA02, potassium citrate, The therapeutic efficacy of Potassium citrate can be decreased when used in combination with Buprenorphine.]
[G04BD06, propiverine, The risk or severity of adverse effects can be increased when Propiverine is combined with Buprenorphine.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Buprenorphine.]
[N05AX07, prothipendyl, Prothipendyl may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[J04AB04, rifabutin, The metabolism of Buprenorphine can be increased when combined with Rifabutin.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Buprenorphine.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Buprenorphine.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Buprenorphine.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Buprenorphine.]
[N01AH03, sufentanil, Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AA02, imipramine, Imipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Buprenorphine.]
[M03BX02, tizanidine, Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01CE01, topotecan, Buprenorphine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be decreased when used in combination with Buprenorphine.]
[S01BC01, indomethacin, The metabolism of Buprenorphine can be decreased when combined with Indomethacin.]
[N06AX17, milnacipran, Milnacipran may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A03AA30, piperidolate, The risk or severity of adverse effects can be increased when Piperidolate is combined with Buprenorphine.]
[N01BB08, articaine, Articaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be decreased when combined with Buprenorphine.]
[N05BA12, alprazolam, Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CH02, ramelteon, Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R06AE01, buclizine, The risk or severity of adverse effects can be increased when Buclizine is combined with Buprenorphine.]
[C10AA06, cerivastatin, Buprenorphine may decrease the excretion rate of Cerivastatin which could result in a higher serum level.]
[C07AA01, alprenolol, Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C03BA02, quinethazone, The therapeutic efficacy of Quinethazone can be decreased when used in combination with Buprenorphine.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Buprenorphine.]
[N06AA13, iprindole, Iprindole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AF05, iproniazid, Iproniazid may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AA07, chlorproethazine, Chlorproethazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[P01AX06, atovaquone, The metabolism of Buprenorphine can be decreased when combined with Atovaquone.]
[N01AB06, isoflurane, Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N04BX02, entacapone, Entacapone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[J04AC01, isoniazid, The metabolism of Buprenorphine can be decreased when combined with Isoniazid.]
[P02CF01, ivermectin, Buprenorphine may decrease the excretion rate of Ivermectin which could result in a higher serum level.]
[N06AX18, reboxetine, Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L04AC07, tocilizumab, The metabolism of Buprenorphine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C02KD01, ketanserin, Ketanserin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be decreased when combined with Buprenorphine.]
[H02CA04, levoketoconazole, The metabolism of Buprenorphine can be decreased when combined with Levoketoconazole.]
[J02AB02, ketoconazole, The metabolism of Buprenorphine can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M02AA10, ketoprofen, The metabolism of Buprenorphine can be decreased when combined with Ketoprofen.]
[V03AC03, deferasirox, The metabolism of Buprenorphine can be decreased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Buprenorphine can be increased when combined with Abatacept.]
[N04BC09, rotigotine, Rotigotine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Buprenorphine.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Amantadine is combined with Buprenorphine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Buprenorphine.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Buprenorphine.]
[N03AX18, lacosamide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Buprenorphine.]
[G03AD01, levonorgestrel, The metabolism of Buprenorphine can be decreased when combined with Levonorgestrel.]
[N04BA01, levodopa, Levodopa may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S02DA01, lidocaine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06BA13, armodafinil, The metabolism of Buprenorphine can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Buprenorphine.]
[C03DB01, amiloride, The therapeutic efficacy of Amiloride can be decreased when used in combination with Buprenorphine.]
[N02CA07, lisuride, Lisuride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AA07, lofepramine, Lofepramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A07DA03, loperamide, The metabolism of Buprenorphine can be decreased when combined with Loperamide.]
[N05BA06, lorazepam, Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Buprenorphine.]
[N05AH01, loxapine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Buprenorphine.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Buprenorphine.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Buprenorphine.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Buprenorphine.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01BA05, pralatrexate, Buprenorphine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Buprenorphine can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The therapeutic efficacy of Mannitol can be decreased when used in combination with Buprenorphine.]
[N06AA21, maprotiline, Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A08AA05, mazindol, Mazindol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Buprenorphine.]
[R06AE05, meclizine, Meclizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BA03, medazepam, Medazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Buprenorphine.]
[C03BA05, mefruside, The therapeutic efficacy of Mefruside can be decreased when used in combination with Buprenorphine.]
[N05CH01, melatonin, Melatonin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02AB02, meperidine, Meperidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C01CA11, mephentermine, Mephentermine may increase the analgesic activities of Buprenorphine.]
[N03AB04, mephenytoin, Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N01BB03, mepivacaine, Mepivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BC01, meprobamate, Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02AX05, meptazinol, Meptazinol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C03BC01, mersalyl, The therapeutic efficacy of Mersalyl can be decreased when used in combination with Buprenorphine.]
[N05AC03, mesoridazine, Mesoridazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AX13, paliperidone, Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A04AA04, dolasetron, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Buprenorphine.]
[N06BA03, methamphetamine, Metamfetamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A03AB07, methantheline, The risk or severity of adverse effects can be increased when Methantheline is combined with Buprenorphine.]
[R06AC05, methapyrilene, Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CM01, methaqualone, Methaqualone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[J05AF05, lamivudine, Buprenorphine may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[N03AA30, metharbital, Metharbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S01EC05, methazolamide, The therapeutic efficacy of Methazolamide can be decreased when used in combination with Buprenorphine.]
[G02CB05, metergoline, Metergoline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[H03BB02, methimazole, The metabolism of Buprenorphine can be decreased when combined with Methimazole.]
[M03BA03, methocarbamol, Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CA15, methohexital, Methohexital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02BG08, ziconotide, Ziconotide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Buprenorphine.]
[N05AA02, methotrimeprazine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Buprenorphine.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Buprenorphine.]
[V04CG05, methylene blue, Buprenorphine may increase the serotonergic activities of Methylene blue.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Buprenorphine.]
[N03AF03, rufinamide, Rufinamide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CE02, methyprylon, Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02CA04, methysergide, Methysergide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A03FA01, metoclopramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Buprenorphine.]
[C03BA08, metolazone, The therapeutic efficacy of Metolazone can be decreased when used in combination with Buprenorphine.]
[C07AB02, metoprolol, The metabolism of Buprenorphine can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The metabolism of Buprenorphine can be decreased when combined with Metronidazole.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Buprenorphine.]
[N06AX03, mianserin, Mianserin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S02AA13, miconazole, The metabolism of Buprenorphine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Buprenorphine.]
[N05CD08, midazolam, Midazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[G03XB01, mifepristone, The serum concentration of Buprenorphine can be increased when it is combined with Mifepristone.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Buprenorphine.]
[C09CA03, valsartan, The metabolism of Buprenorphine can be decreased when combined with Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01XX23, mitotane, The metabolism of Buprenorphine can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, Buprenorphine may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may increase the analgesic activities of Buprenorphine.]
[N05AE02, molindone, Molindone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C01BD01, amiodarone, The metabolism of Buprenorphine can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02AA01, morphine, Morphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A04AA05, palonosetron, Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L04AB05, certolizumab pegol, The metabolism of Buprenorphine can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Buprenorphine can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Buprenorphine.]
[M03AC03, vecuronium, Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CA02, amobarbital, Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[P01BA06, amodiaquine, The metabolism of Buprenorphine can be decreased when combined with Amodiaquine.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Ipratropium is combined with Buprenorphine.]
[G03XC01, raloxifene, Buprenorphine may decrease the excretion rate of Raloxifene which could result in a higher serum level.]
[N06AA17, amoxapine, Amoxapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N03AB05, fosphenytoin, Fosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C07AA12, nadolol, The metabolism of Nadolol can be decreased when combined with Buprenorphine.]
[N04BC04, ropinirole, Buprenorphine may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, Naftidrofuryl may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02AF02, nalbuphine, Nalbuphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N07BB04, naltrexone, The therapeutic efficacy of Naltrexone can be decreased when used in combination with Buprenorphine.]
[L04AC03, anakinra, The metabolism of Buprenorphine can be increased when combined with Anakinra.]
[S01GA01, naphazoline, Naphazoline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06BA01, amphetamine, Amphetamine may increase the analgesic activities of Buprenorphine.]
[M02AA12, naproxen, The metabolism of Buprenorphine can be decreased when combined with Naproxen.]
[A10BG01, troglitazone, The metabolism of Buprenorphine can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N04BX01, tolcapone, Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Buprenorphine.]
[N01AH06, remifentanil, Remifentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A10BX02, repaglinide, The metabolism of Buprenorphine can be decreased when combined with Repaglinide.]
[N05AX14, iloperidone, Iloperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AX23, desvenlafaxine, Desvenlafaxine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C10AD02, niacin, The metabolism of Buprenorphine can be decreased when combined with Niacin.]
[N06AF02, nialamide, Nialamide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C08CA04, nicardipine, The risk or severity of adverse effects can be increased when Nicardipine is combined with Buprenorphine.]
[C04AE02, nicergoline, The metabolism of Nicergoline can be decreased when combined with Buprenorphine.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Buprenorphine.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be decreased when combined with Buprenorphine.]
[M02AA17, niflumic acid, The metabolism of Buprenorphine can be decreased when combined with Niflumic acid.]
[C08CA07, nisoldipine, The metabolism of Buprenorphine can be decreased when combined with Nisoldipine.]
[N05CD02, nitrazepam, Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C08CA08, nitrendipine, The metabolism of Nitrendipine can be decreased when combined with Buprenorphine.]
[J01XE01, nitrofurantoin, Buprenorphine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N04BC05, pramipexole, Buprenorphine may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AX04, nomifensine, Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Buprenorphine.]
[C02KX01, bosentan, The metabolism of Buprenorphine can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, Nortriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R05DA07, noscapine, The metabolism of Buprenorphine can be decreased when combined with Noscapine.]
[L04AC04, rilonacept, The metabolism of Buprenorphine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Buprenorphine.]
[N06AA05, opipramol, Opipramol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02AA02, opium, Opium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Buprenorphine.]
[P02BA02, oxamniquine, The metabolism of Buprenorphine can be decreased when combined with Oxamniquine.]
[A14AA08, oxandrolone, The metabolism of Buprenorphine can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C07AA02, oxprenolol, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02AA05, oxycodone, Oxycodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02AA11, oxymorphone, Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AE01, oxypertine, Oxypertine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A03AB03, oxyphenonium, The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Buprenorphine.]
[N05AH05, asenapine, Asenapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M03AC01, pancuronium, Pancuronium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CC05, paraldehyde, Paraldehyde may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[H02AB05, paramethasone, The metabolism of Buprenorphine can be increased when combined with Paramethasone.]
[C02KC01, pargyline, Pargyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[G04BD11, fesoterodine, The risk or severity of adverse effects can be increased when Fesoterodine is combined with Buprenorphine.]
[C07AA23, penbutolol, Penbutolol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AG03, penfluridol, Penfluridol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02AD01, pentazocine, Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CA01, pentobarbital, Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05AB10, perazine, Perazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N04BC02, pergolide, Pergolide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C08EX02, perhexiline, The metabolism of Buprenorphine can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Buprenorphine.]
[N02AD02, phenazocine, Phenazocine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N06AF03, phenelzine, Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Buprenorphine.]
[N03AA02, phenobarbital, Phenobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Buprenorphine.]
[N01AH04, phenoperidine, Phenoperidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Buprenorphine.]
[A08AA01, phentermine, Phentermine may increase the analgesic activities of Buprenorphine.]
[M02AA01, phenylbutazone, The metabolism of Buprenorphine can be decreased when combined with Phenylbutazone.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Buprenorphine.]
[N03AB02, phenytoin, Phenytoin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L04AB06, golimumab, The metabolism of Buprenorphine can be increased when combined with Golimumab.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Buprenorphine.]
[C08CX01, mibefradil, The metabolism of Buprenorphine can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, Pimozide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C07AA03, pindolol, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Buprenorphine.]
[J05AE01, saquinavir, The metabolism of Buprenorphine can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Buprenorphine.]
[N05AC04, pipothiazine, Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A02BX03, pirenzepine, The risk or severity of adverse effects can be increased when Pirenzepine is combined with Buprenorphine.]
[N02AC03, pirinitramide, Piritramide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[S01BC06, piroxicam, The metabolism of Buprenorphine can be decreased when combined with Piroxicam.]
[N02CX01, pizotyline, Pizotifen may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[J05AG02, delavirdine, The metabolism of Buprenorphine can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Buprenorphine can be decreased when combined with Irbesartan.]
[N05CA22, proxibarbal, Proxibarbal may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[D05AX05, tazarotene, The metabolism of Buprenorphine can be decreased when combined with Tazarotene.]
[A10BG02, rosiglitazone, The metabolism of Buprenorphine can be decreased when combined with Rosiglitazone.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Buprenorphine.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Buprenorphine.]
[A03AE01, alosetron, Alosetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L04AC08, canakinumab, The metabolism of Buprenorphine can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The therapeutic efficacy of Polythiazide can be decreased when used in combination with Buprenorphine.]
[J05AE03, ritonavir, The serum concentration of Buprenorphine can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Saxagliptin can be decreased when combined with Buprenorphine.]
[C10AA08, pitavastatin, Buprenorphine may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[C07AB01, practolol, The metabolism of Practolol can be decreased when combined with Buprenorphine.]
[N05BA11, prazepam, Prazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Buprenorphine.]
[C02CA01, prazosin, Buprenorphine may decrease the excretion rate of Prazosin which could result in a higher serum level.]
[N01BB04, prilocaine, Prilocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[P01BA03, primaquine, The metabolism of Buprenorphine can be decreased when combined with Primaquine.]
[N03AA03, primidone, Primidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M04AB01, probenecid, The metabolism of Buprenorphine can be decreased when combined with Probenecid.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Buprenorphine.]
[S01HA05, procaine, Procaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01XB01, procarbazine, Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C10AB05, fenofibrate, The metabolism of Buprenorphine can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N04AA04, procyclidine, The risk or severity of adverse effects can be increased when Procyclidine is combined with Buprenorphine.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Buprenorphine.]
[N05AA03, promazine, Promazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R06AD02, promethazine, Promethazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C01BC03, propafenone, The metabolism of Buprenorphine can be decreased when combined with Propafenone.]
[N01AX04, propanidid, Propanidid may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A03AB05, propantheline, The risk or severity of adverse effects can be increased when Propantheline is combined with Buprenorphine.]
[N05AC01, periciazine, Periciazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CM06, propiomazine, Propiomazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Buprenorphine.]
[N01AX10, propofol, Propofol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N02AC04, propoxyphene, Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Buprenorphine.]
[N02CC04, rizatriptan, Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R03DC03, montelukast, The metabolism of Buprenorphine can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R01BA02, pseudoephedrine, Pseudoephedrine may increase the analgesic activities of Buprenorphine.]
[N05AX12, aripiprazole, Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A03AB15, diphemanil, The risk or severity of adverse effects can be increased when Diphemanil is combined with Buprenorphine.]
[A03AB09, isopropamide, The risk or severity of adverse effects can be increased when Isopropamide is combined with Buprenorphine.]
[S01FA03, methscopolamine, The risk or severity of adverse effects can be increased when Methscopolamine is combined with Buprenorphine.]
[N05CA07, talbutal, Talbutal may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CA09, vinbarbital, Vinbarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BB02, captodiamine, Captodiame may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[M03BA04, styramate, Styramate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[P02CC01, pyrantel, Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[R06AC01, pyrilamine, Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[P01BD01, pyrimethamine, The metabolism of Buprenorphine can be decreased when combined with Pyrimethamine.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be decreased when combined with Buprenorphine.]
[C01BA01, quinidine, The risk or severity of adverse effects can be increased when Quinidine is combined with Buprenorphine.]
[P01BC01, quinine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A02BA02, ranitidine, The metabolism of Buprenorphine can be decreased when combined with Ranitidine.]
[C02AA02, reserpine, Reserpine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[J04AB02, rifampin, The metabolism of Buprenorphine can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[A07EC01, sulfasalazine, Buprenorphine may decrease the excretion rate of Sulfasalazine which could result in a higher serum level.]
[S01BC08, salicylic acid, The metabolism of Salicylic acid can be decreased when combined with Buprenorphine.]
[S01FA02, scopolamine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05CA06, secobarbital, Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N04BD01, selegiline, Selegiline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Buprenorphine.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Buprenorphine.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Buprenorphine.]
[C03DA01, spironolactone, The metabolism of Buprenorphine can be decreased when combined with Spironolactone.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Buprenorphine.]
[N03AG01, valproic acid, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[D07AB02, hydrocortisone butyrate, The metabolism of Hydrocortisone butyrate can be decreased when combined with Buprenorphine.]
